From Wikipedia, the free encyclopedia
Jump to: navigation, search
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD44 v6
ATC code none
ChemSpider none

Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6.[1][2]

It is officially described as "immunoglobulin G1 (human-mouse monoclonal BIWA4 γ1-chain anti-human antigen CD44v6), disulfide with human-mouse monoclonal BIWA4 κ-chain, dimer".[3] Prior to 2002 it was described as targeting CD44 v8.[4]

It has been chemically linked to various radioisotopes for use in radiotherapy for, e.g. inoperable recurrent or metastatic head and neck cancer.[1]

It has also been linked to a cytotoxic drug mertansine to form bivatuzumab mertansine.